Early hormonal data from a multicentre phase II trial using transdermal oestrogen patches as first-line hormonal therapy in patients with locally advanced or metastatic prostate cancer

BJU International

Volumn 102, Issue 4, 2008, Pages 442-445

  Langley, Ruth E ^a,i   Godsland, Ian F ^a   Kynaston, Howard ^b   Clarke, Noel W ^c   Rosen, Stuart D ^d   Morgan, Rachel C ^a   Pollock, Philip ^a   Kockelbergh, Roger ^e   Lalani, El Nasir ^f   Dearnaley, David ^g   Parmar, Mahesh ^a   Abel, Paul D ^h  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY HOSPITAL OF WALES   (United Kingdom)

^c CHRISTIE HOSPITAL   (United Kingdom)

^d ROYAL BROMPTON AND HAREFIELD NHS FOUNDATION TRUST   (United Kingdom)

^e UNIVERSITY HOSPITALS OF LEICESTER NHS TRUST   (United Kingdom)

^f UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^g ROYAL MARSDEN HOSPITAL   (United Kingdom)

^h IMPERIAL COLLEGE HEALTHCARE NHS TRUST   (United Kingdom)

ⁱ MRC CLINICAL TRIALS UNIT   (United Kingdom)

Author keywords

Hormone therapy; Prostate cancer; Randomized controlled trial; Transdermal oestrogen patches

Indexed keywords

ANDROGEN; ESTRADIOL; ESTRADOT; ESTROGEN; FEM7; GONADORELIN AGONIST; PROSTATE SPECIFIC ANTIGEN; TESTOSTERONE;

ADULT; AGED; ARTICLE; CANCER PATIENT; CASTRATED MALE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; ESTRADIOL BLOOD LEVEL; FOLLOW UP; HORMONE RESPONSE; HUMAN; MALE; METASTASIS; MULTICENTER STUDY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROSTATE CANCER; RANDOMIZED CONTROLLED TRIAL; TESTOSTERONE BLOOD LEVEL;

ADMINISTRATION, CUTANEOUS; AGED; ANDROGEN ANTAGONISTS; ANDROGENS; ANTINEOPLASTIC AGENTS, HORMONAL; ESTRADIOL; ESTROGENS; GONADOTROPIN-RELEASING HORMONE; HUMANS; MALE; MIDDLE AGED; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; TESTOSTERONE; TREATMENT OUTCOME;

EID: 47749105752     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2008.07583.x     Document Type: Article

References (19)

1. Carroll PR, Lee K, Fuks ZY, Kantoff PW. Cancer of the prostate. In DeVita VT, Hellman S, Rosenberg SA, Cancer: Principles and Practice of Oncology, 6th edn. Philadelphia : Lippincott, Williams and Wilkins, 2001 : 1435 64
2. Krupski TL, Smith MR, Chan Lee W et al. Natural history of bone complications in men with prostate carcinoma initiating androgen deprivation therapy. Cancer 2004 101 : 541 9
3. Byar DP. Proceedings: the Veterans Administration Cooperative Urological Research Group's studies of cancer of the prostate. Cancer 1973 32 : 1126 30
4. Von Schoultz B, Carlstrom K, Collste L et al. Estrogen therapy and liver function-metabolic effects of oral and parenteral administration. Prostate 1989 14 : 389 95
5. Ockrim JL, Lalani EN, Laniado ME, Carter SS, Abel PD. Transdermal estradiol therapy for advanced prostate cancer - forward to the past? J Urol 2003 169 : 1735 7
6. Ockrim JL, Lalani EN, Banks LM et al. Transdermal estradiol improves bone density when used as single agent therapy for prostate cancer. J Urol 2004 172 : 2203 7
7. Kandola S, Anyamene N, Payne H, Harland S. Transdermal oestrogen therapy as a second-line hormonal intervention in prostate cancer: a bad experience. BJU Int 2007 99 : 53 5
8. Oefelein MG, Feng A, Scolieri MJ, Ricchiutti D, Resnick MI. Reassessment of the definition of castrate levels of testosterone: implications for clinical decision making. Urology 2000 56 : 1021 4
9. Stege R, Carlstrom K, Collste L, Eriksson A, Henriksson P, Posette A. Single drug polyestradiol phosphate therapy in prostate cancer. Am J Clin Oncol 1988 11 : S101 3
10. eMC. Electronic Medicines Compendium. SPC data sheets (Progynova TS 100 and Evorel 100). Available at: http://emc.medicines.org.uk/. Accessed June 2007
11. Geyer D, Gerrits MG, Renoux A, Uhl W. Pharmacokinetics of Fem7, a once-weekly, transdermal oestrogen replacement system in healthy, postmenopausal women. Gynecol Obstet Invest 1999 48 : 1 6
12. Reginster JY, Albert A, Deroisy R et al. Plasma estradiol concentrations and pharmacokinetics following transdermal application of Menorest 50 or Systen (Evorel) 50. Maturitas 1997 27 : 179 86
13. Hossain M, Quebe-Fehling E, Sergejew T et al. Dose proportionality study of four doses of an estradiol transdermal system, Estradot. Maturitas 2003 46 : 173 85
14. Oefelein MG, Cornum R. Failure to achieve castrate levels of testosterone during luteinizing hormone releasing hormone agonist therapy: the case for monitoring serum testosterone and a treatment decision algorithm. J Urol 2000 164 : 726 9
15. Ockrim J. Transdermal oestradiol therapy for the treatment of advanced prostate cancer. MD Thesis. University of London, 2003
16. Malkowicz SB. The role of diethylstilboestrol in the treatment of prostate cancer. Urology 2001 58 (Suppl. 2A 108 13
17. Scherr DS, Pitts WR Jr. The nonsteroidal effects of diethylstilbestrol: the rationale for androgen deprivation therapy without estrogen deprivation in the treatment of prostate cancer. J Urol 2003 170 : 1703 8
18. Robertson CN, Roberson KM, Padilla GM et al. Induction of apoptosis by diethylstilbestrol in hormone-insensitive prostate cancer cells. JNCI 1996 88 : 908 17
19. Kalach J, Joly-Pharaboz M, Chantepie J et al. Divergent biological effects of estradiol and diethylstilbestrol in prostate cancer cell line MOP. J Steroid Biochem Mol Biol 2005 96 : 119 29